nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—atherosclerosis	0.35	1	CbGaD
Lenalidomide—ABCB1—Ezetimibe—atherosclerosis	0.048	0.267	CbGbCtD
Lenalidomide—ABCB1—Simvastatin—atherosclerosis	0.0447	0.248	CbGbCtD
Lenalidomide—ABCB1—Pravastatin—atherosclerosis	0.0437	0.243	CbGbCtD
Lenalidomide—ABCB1—Lovastatin—atherosclerosis	0.0437	0.243	CbGbCtD
Lenalidomide—TNFSF11—leg—atherosclerosis	0.0234	0.188	CbGeAlD
Lenalidomide—TNFSF11—hindlimb—atherosclerosis	0.0209	0.168	CbGeAlD
Lenalidomide—TNFSF11—appendage—atherosclerosis	0.018	0.144	CbGeAlD
Lenalidomide—CDH5—artery—atherosclerosis	0.00965	0.0775	CbGeAlD
Lenalidomide—CDH5—endothelium—atherosclerosis	0.00816	0.0655	CbGeAlD
Lenalidomide—CDH5—blood vessel—atherosclerosis	0.00752	0.0604	CbGeAlD
Lenalidomide—TNFSF11—connective tissue—atherosclerosis	0.00513	0.0411	CbGeAlD
Lenalidomide—CDH5—connective tissue—atherosclerosis	0.00386	0.031	CbGeAlD
Lenalidomide—Thalidomide—NFKB1—atherosclerosis	0.00358	0.464	CrCbGaD
Lenalidomide—CDH5—cardiovascular system—atherosclerosis	0.00336	0.0269	CbGeAlD
Lenalidomide—PTGS2—leg—atherosclerosis	0.00305	0.0245	CbGeAlD
Lenalidomide—CDH5—adipose tissue—atherosclerosis	0.00296	0.0237	CbGeAlD
Lenalidomide—PTGS2—hindlimb—atherosclerosis	0.00272	0.0219	CbGeAlD
Lenalidomide—PTGS2—appendage—atherosclerosis	0.00234	0.0188	CbGeAlD
Lenalidomide—CDH5—liver—atherosclerosis	0.00207	0.0167	CbGeAlD
Lenalidomide—CRBN—adipose tissue—atherosclerosis	0.00188	0.0151	CbGeAlD
Lenalidomide—Pomalidomide—TNF—atherosclerosis	0.0017	0.221	CrCbGaD
Lenalidomide—PTGS2—artery—atherosclerosis	0.00167	0.0134	CbGeAlD
Lenalidomide—PTGS2—endothelium—atherosclerosis	0.00141	0.0113	CbGeAlD
Lenalidomide—CRBN—liver—atherosclerosis	0.00132	0.0106	CbGeAlD
Lenalidomide—PTGS2—blood vessel—atherosclerosis	0.0013	0.0104	CbGeAlD
Lenalidomide—Thalidomide—TNF—atherosclerosis	0.0011	0.142	CrCbGaD
Lenalidomide—Pomalidomide—PTGS2—atherosclerosis	0.000808	0.105	CrCbGaD
Lenalidomide—ABCB1—blood vessel—atherosclerosis	0.000805	0.00646	CbGeAlD
Lenalidomide—PTGS2—connective tissue—atherosclerosis	0.000667	0.00535	CbGeAlD
Lenalidomide—PTGS2—cardiovascular system—atherosclerosis	0.00058	0.00466	CbGeAlD
Lenalidomide—Thalidomide—PTGS2—atherosclerosis	0.000521	0.0676	CrCbGaD
Lenalidomide—PTGS2—adipose tissue—atherosclerosis	0.000512	0.00411	CbGeAlD
Lenalidomide—ABCB1—cardiovascular system—atherosclerosis	0.000359	0.00288	CbGeAlD
Lenalidomide—PTGS2—liver—atherosclerosis	0.000359	0.00288	CbGeAlD
Lenalidomide—ABCB1—adipose tissue—atherosclerosis	0.000317	0.00254	CbGeAlD
Lenalidomide—Anaemia—Ezetimibe—atherosclerosis	0.000297	0.00146	CcSEcCtD
Lenalidomide—Tinnitus—Pravastatin—atherosclerosis	0.000297	0.00146	CcSEcCtD
Lenalidomide—Malaise—Lovastatin—atherosclerosis	0.000296	0.00145	CcSEcCtD
Lenalidomide—Cardiac disorder—Pravastatin—atherosclerosis	0.000296	0.00145	CcSEcCtD
Lenalidomide—Flushing—Pravastatin—atherosclerosis	0.000296	0.00145	CcSEcCtD
Lenalidomide—Muscle spasms—Simvastatin—atherosclerosis	0.000295	0.00145	CcSEcCtD
Lenalidomide—Vertigo—Lovastatin—atherosclerosis	0.000295	0.00144	CcSEcCtD
Lenalidomide—Angioedema—Ezetimibe—atherosclerosis	0.000294	0.00144	CcSEcCtD
Lenalidomide—Angiopathy—Niacin—atherosclerosis	0.000293	0.00144	CcSEcCtD
Lenalidomide—Leukopenia—Lovastatin—atherosclerosis	0.000293	0.00144	CcSEcCtD
Lenalidomide—Chills—Niacin—atherosclerosis	0.00029	0.00142	CcSEcCtD
Lenalidomide—Malaise—Ezetimibe—atherosclerosis	0.00029	0.00142	CcSEcCtD
Lenalidomide—Vision blurred—Simvastatin—atherosclerosis	0.000289	0.00142	CcSEcCtD
Lenalidomide—Arrhythmia—Niacin—atherosclerosis	0.000289	0.00142	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000288	0.00141	CcSEcCtD
Lenalidomide—Tremor—Simvastatin—atherosclerosis	0.000287	0.00141	CcSEcCtD
Lenalidomide—Alopecia—Niacin—atherosclerosis	0.000286	0.0014	CcSEcCtD
Lenalidomide—Chills—Pravastatin—atherosclerosis	0.000286	0.0014	CcSEcCtD
Lenalidomide—Insomnia—Rosuvastatin—atherosclerosis	0.000286	0.0014	CcSEcCtD
Lenalidomide—Ill-defined disorder—Simvastatin—atherosclerosis	0.000285	0.00139	CcSEcCtD
Lenalidomide—Arrhythmia—Pravastatin—atherosclerosis	0.000285	0.00139	CcSEcCtD
Lenalidomide—Palpitations—Ezetimibe—atherosclerosis	0.000284	0.00139	CcSEcCtD
Lenalidomide—Paraesthesia—Rosuvastatin—atherosclerosis	0.000284	0.00139	CcSEcCtD
Lenalidomide—Anaemia—Simvastatin—atherosclerosis	0.000283	0.00139	CcSEcCtD
Lenalidomide—Erythema—Niacin—atherosclerosis	0.000282	0.00138	CcSEcCtD
Lenalidomide—Malnutrition—Niacin—atherosclerosis	0.000282	0.00138	CcSEcCtD
Lenalidomide—Alopecia—Pravastatin—atherosclerosis	0.000281	0.00138	CcSEcCtD
Lenalidomide—Cough—Ezetimibe—atherosclerosis	0.000281	0.00138	CcSEcCtD
Lenalidomide—Angioedema—Simvastatin—atherosclerosis	0.00028	0.00137	CcSEcCtD
Lenalidomide—Chest pain—Lovastatin—atherosclerosis	0.000279	0.00137	CcSEcCtD
Lenalidomide—Arthralgia—Lovastatin—atherosclerosis	0.000279	0.00137	CcSEcCtD
Lenalidomide—Myalgia—Lovastatin—atherosclerosis	0.000279	0.00137	CcSEcCtD
Lenalidomide—Anxiety—Lovastatin—atherosclerosis	0.000278	0.00136	CcSEcCtD
Lenalidomide—Dyspepsia—Rosuvastatin—atherosclerosis	0.000278	0.00136	CcSEcCtD
Lenalidomide—Hypertension—Ezetimibe—atherosclerosis	0.000278	0.00136	CcSEcCtD
Lenalidomide—Flatulence—Niacin—atherosclerosis	0.000277	0.00136	CcSEcCtD
Lenalidomide—Malaise—Simvastatin—atherosclerosis	0.000277	0.00136	CcSEcCtD
Lenalidomide—Tension—Niacin—atherosclerosis	0.000276	0.00135	CcSEcCtD
Lenalidomide—Discomfort—Lovastatin—atherosclerosis	0.000276	0.00135	CcSEcCtD
Lenalidomide—Vertigo—Simvastatin—atherosclerosis	0.000276	0.00135	CcSEcCtD
Lenalidomide—Leukopenia—Simvastatin—atherosclerosis	0.000275	0.00135	CcSEcCtD
Lenalidomide—Myalgia—Ezetimibe—atherosclerosis	0.000274	0.00134	CcSEcCtD
Lenalidomide—Chest pain—Ezetimibe—atherosclerosis	0.000274	0.00134	CcSEcCtD
Lenalidomide—Arthralgia—Ezetimibe—atherosclerosis	0.000274	0.00134	CcSEcCtD
Lenalidomide—Nervousness—Niacin—atherosclerosis	0.000274	0.00134	CcSEcCtD
Lenalidomide—Flatulence—Pravastatin—atherosclerosis	0.000273	0.00134	CcSEcCtD
Lenalidomide—Dry mouth—Lovastatin—atherosclerosis	0.000273	0.00134	CcSEcCtD
Lenalidomide—Tension—Pravastatin—atherosclerosis	0.000272	0.00133	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000272	0.00133	CcSEcCtD
Lenalidomide—Dysgeusia—Pravastatin—atherosclerosis	0.000272	0.00133	CcSEcCtD
Lenalidomide—Muscle spasms—Niacin—atherosclerosis	0.000271	0.00133	CcSEcCtD
Lenalidomide—Discomfort—Ezetimibe—atherosclerosis	0.000271	0.00133	CcSEcCtD
Lenalidomide—Constipation—Rosuvastatin—atherosclerosis	0.00027	0.00132	CcSEcCtD
Lenalidomide—Pain—Rosuvastatin—atherosclerosis	0.00027	0.00132	CcSEcCtD
Lenalidomide—Confusional state—Lovastatin—atherosclerosis	0.00027	0.00132	CcSEcCtD
Lenalidomide—Nervousness—Pravastatin—atherosclerosis	0.000269	0.00132	CcSEcCtD
Lenalidomide—Dry mouth—Ezetimibe—atherosclerosis	0.000268	0.00131	CcSEcCtD
Lenalidomide—Muscle spasms—Pravastatin—atherosclerosis	0.000267	0.00131	CcSEcCtD
Lenalidomide—Infection—Lovastatin—atherosclerosis	0.000266	0.0013	CcSEcCtD
Lenalidomide—Vision blurred—Niacin—atherosclerosis	0.000265	0.0013	CcSEcCtD
Lenalidomide—Confusional state—Ezetimibe—atherosclerosis	0.000265	0.0013	CcSEcCtD
Lenalidomide—Thrombocytopenia—Lovastatin—atherosclerosis	0.000262	0.00128	CcSEcCtD
Lenalidomide—Vision blurred—Pravastatin—atherosclerosis	0.000261	0.00128	CcSEcCtD
Lenalidomide—Chest pain—Simvastatin—atherosclerosis	0.000261	0.00128	CcSEcCtD
Lenalidomide—Arthralgia—Simvastatin—atherosclerosis	0.000261	0.00128	CcSEcCtD
Lenalidomide—Myalgia—Simvastatin—atherosclerosis	0.000261	0.00128	CcSEcCtD
Lenalidomide—Infection—Ezetimibe—atherosclerosis	0.000261	0.00128	CcSEcCtD
Lenalidomide—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00026	0.00128	CcSEcCtD
Lenalidomide—Anxiety—Simvastatin—atherosclerosis	0.00026	0.00128	CcSEcCtD
Lenalidomide—Tremor—Pravastatin—atherosclerosis	0.00026	0.00127	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000258	0.00127	CcSEcCtD
Lenalidomide—Discomfort—Simvastatin—atherosclerosis	0.000258	0.00126	CcSEcCtD
Lenalidomide—Nervous system disorder—Ezetimibe—atherosclerosis	0.000257	0.00126	CcSEcCtD
Lenalidomide—Angioedema—Niacin—atherosclerosis	0.000257	0.00126	CcSEcCtD
Lenalidomide—Ill-defined disorder—Pravastatin—atherosclerosis	0.000257	0.00126	CcSEcCtD
Lenalidomide—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000257	0.00126	CcSEcCtD
Lenalidomide—Anaemia—Pravastatin—atherosclerosis	0.000256	0.00126	CcSEcCtD
Lenalidomide—Anorexia—Lovastatin—atherosclerosis	0.000255	0.00125	CcSEcCtD
Lenalidomide—Skin disorder—Ezetimibe—atherosclerosis	0.000255	0.00125	CcSEcCtD
Lenalidomide—Angioedema—Pravastatin—atherosclerosis	0.000253	0.00124	CcSEcCtD
Lenalidomide—Vertigo—Niacin—atherosclerosis	0.000253	0.00124	CcSEcCtD
Lenalidomide—Syncope—Niacin—atherosclerosis	0.000253	0.00124	CcSEcCtD
Lenalidomide—Confusional state—Simvastatin—atherosclerosis	0.000252	0.00124	CcSEcCtD
Lenalidomide—Leukopenia—Niacin—atherosclerosis	0.000252	0.00124	CcSEcCtD
Lenalidomide—Urticaria—Rosuvastatin—atherosclerosis	0.000251	0.00123	CcSEcCtD
Lenalidomide—Oedema—Simvastatin—atherosclerosis	0.00025	0.00123	CcSEcCtD
Lenalidomide—Malaise—Pravastatin—atherosclerosis	0.00025	0.00123	CcSEcCtD
Lenalidomide—Abdominal pain—Rosuvastatin—atherosclerosis	0.00025	0.00122	CcSEcCtD
Lenalidomide—Vertigo—Pravastatin—atherosclerosis	0.000249	0.00122	CcSEcCtD
Lenalidomide—Palpitations—Niacin—atherosclerosis	0.000249	0.00122	CcSEcCtD
Lenalidomide—Infection—Simvastatin—atherosclerosis	0.000249	0.00122	CcSEcCtD
Lenalidomide—Leukopenia—Pravastatin—atherosclerosis	0.000248	0.00122	CcSEcCtD
Lenalidomide—Loss of consciousness—Niacin—atherosclerosis	0.000248	0.00121	CcSEcCtD
Lenalidomide—Cough—Niacin—atherosclerosis	0.000246	0.0012	CcSEcCtD
Lenalidomide—Thrombocytopenia—Simvastatin—atherosclerosis	0.000245	0.0012	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000244	0.0012	CcSEcCtD
Lenalidomide—Insomnia—Lovastatin—atherosclerosis	0.000242	0.00119	CcSEcCtD
Lenalidomide—Cough—Pravastatin—atherosclerosis	0.000242	0.00119	CcSEcCtD
Lenalidomide—Paraesthesia—Lovastatin—atherosclerosis	0.00024	0.00118	CcSEcCtD
Lenalidomide—Arthralgia—Niacin—atherosclerosis	0.00024	0.00118	CcSEcCtD
Lenalidomide—Myalgia—Niacin—atherosclerosis	0.00024	0.00118	CcSEcCtD
Lenalidomide—Hypertension—Pravastatin—atherosclerosis	0.000239	0.00117	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000239	0.00117	CcSEcCtD
Lenalidomide—Anorexia—Simvastatin—atherosclerosis	0.000239	0.00117	CcSEcCtD
Lenalidomide—Dyspnoea—Lovastatin—atherosclerosis	0.000239	0.00117	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000238	0.00117	CcSEcCtD
Lenalidomide—Insomnia—Ezetimibe—atherosclerosis	0.000237	0.00116	CcSEcCtD
Lenalidomide—Myalgia—Pravastatin—atherosclerosis	0.000236	0.00116	CcSEcCtD
Lenalidomide—Chest pain—Pravastatin—atherosclerosis	0.000236	0.00116	CcSEcCtD
Lenalidomide—Arthralgia—Pravastatin—atherosclerosis	0.000236	0.00116	CcSEcCtD
Lenalidomide—Paraesthesia—Ezetimibe—atherosclerosis	0.000236	0.00116	CcSEcCtD
Lenalidomide—Dyspepsia—Lovastatin—atherosclerosis	0.000236	0.00115	CcSEcCtD
Lenalidomide—Anxiety—Pravastatin—atherosclerosis	0.000235	0.00115	CcSEcCtD
Lenalidomide—Dry mouth—Niacin—atherosclerosis	0.000234	0.00115	CcSEcCtD
Lenalidomide—Dyspnoea—Ezetimibe—atherosclerosis	0.000234	0.00115	CcSEcCtD
Lenalidomide—Discomfort—Pravastatin—atherosclerosis	0.000233	0.00114	CcSEcCtD
Lenalidomide—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000233	0.00114	CcSEcCtD
Lenalidomide—Decreased appetite—Lovastatin—atherosclerosis	0.000233	0.00114	CcSEcCtD
Lenalidomide—Dyspepsia—Ezetimibe—atherosclerosis	0.000231	0.00113	CcSEcCtD
Lenalidomide—Fatigue—Lovastatin—atherosclerosis	0.000231	0.00113	CcSEcCtD
Lenalidomide—Oedema—Niacin—atherosclerosis	0.00023	0.00113	CcSEcCtD
Lenalidomide—Constipation—Lovastatin—atherosclerosis	0.000229	0.00112	CcSEcCtD
Lenalidomide—Pain—Lovastatin—atherosclerosis	0.000229	0.00112	CcSEcCtD
Lenalidomide—Confusional state—Pravastatin—atherosclerosis	0.000228	0.00112	CcSEcCtD
Lenalidomide—Decreased appetite—Ezetimibe—atherosclerosis	0.000228	0.00112	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000228	0.00112	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000227	0.00111	CcSEcCtD
Lenalidomide—Asthenia—Rosuvastatin—atherosclerosis	0.000227	0.00111	CcSEcCtD
Lenalidomide—Insomnia—Simvastatin—atherosclerosis	0.000226	0.00111	CcSEcCtD
Lenalidomide—Oedema—Pravastatin—atherosclerosis	0.000226	0.00111	CcSEcCtD
Lenalidomide—Fatigue—Ezetimibe—atherosclerosis	0.000226	0.00111	CcSEcCtD
Lenalidomide—Shock—Niacin—atherosclerosis	0.000226	0.00111	CcSEcCtD
Lenalidomide—Infection—Pravastatin—atherosclerosis	0.000225	0.0011	CcSEcCtD
Lenalidomide—Paraesthesia—Simvastatin—atherosclerosis	0.000225	0.0011	CcSEcCtD
Lenalidomide—Pain—Ezetimibe—atherosclerosis	0.000224	0.0011	CcSEcCtD
Lenalidomide—Constipation—Ezetimibe—atherosclerosis	0.000224	0.0011	CcSEcCtD
Lenalidomide—Tachycardia—Niacin—atherosclerosis	0.000224	0.0011	CcSEcCtD
Lenalidomide—Pruritus—Rosuvastatin—atherosclerosis	0.000223	0.0011	CcSEcCtD
Lenalidomide—Skin disorder—Niacin—atherosclerosis	0.000223	0.00109	CcSEcCtD
Lenalidomide—Dyspnoea—Simvastatin—atherosclerosis	0.000223	0.00109	CcSEcCtD
Lenalidomide—Hyperhidrosis—Niacin—atherosclerosis	0.000222	0.00109	CcSEcCtD
Lenalidomide—ABCB1—liver—atherosclerosis	0.000222	0.00178	CbGeAlD
Lenalidomide—Thrombocytopenia—Pravastatin—atherosclerosis	0.000222	0.00109	CcSEcCtD
Lenalidomide—Feeling abnormal—Lovastatin—atherosclerosis	0.000221	0.00108	CcSEcCtD
Lenalidomide—Dyspepsia—Simvastatin—atherosclerosis	0.00022	0.00108	CcSEcCtD
Lenalidomide—Anorexia—Niacin—atherosclerosis	0.000219	0.00107	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000219	0.00107	CcSEcCtD
Lenalidomide—Hyperhidrosis—Pravastatin—atherosclerosis	0.000219	0.00107	CcSEcCtD
Lenalidomide—Decreased appetite—Simvastatin—atherosclerosis	0.000218	0.00107	CcSEcCtD
Lenalidomide—Feeling abnormal—Ezetimibe—atherosclerosis	0.000216	0.00106	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000216	0.00106	CcSEcCtD
Lenalidomide—Diarrhoea—Rosuvastatin—atherosclerosis	0.000216	0.00106	CcSEcCtD
Lenalidomide—Fatigue—Simvastatin—atherosclerosis	0.000216	0.00106	CcSEcCtD
Lenalidomide—Anorexia—Pravastatin—atherosclerosis	0.000216	0.00106	CcSEcCtD
Lenalidomide—Hypotension—Niacin—atherosclerosis	0.000215	0.00105	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000215	0.00105	CcSEcCtD
Lenalidomide—Constipation—Simvastatin—atherosclerosis	0.000214	0.00105	CcSEcCtD
Lenalidomide—Pain—Simvastatin—atherosclerosis	0.000214	0.00105	CcSEcCtD
Lenalidomide—Urticaria—Lovastatin—atherosclerosis	0.000213	0.00104	CcSEcCtD
Lenalidomide—Abdominal pain—Lovastatin—atherosclerosis	0.000212	0.00104	CcSEcCtD
Lenalidomide—Body temperature increased—Lovastatin—atherosclerosis	0.000212	0.00104	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000209	0.00103	CcSEcCtD
Lenalidomide—Dizziness—Rosuvastatin—atherosclerosis	0.000209	0.00102	CcSEcCtD
Lenalidomide—Urticaria—Ezetimibe—atherosclerosis	0.000209	0.00102	CcSEcCtD
Lenalidomide—Insomnia—Niacin—atherosclerosis	0.000208	0.00102	CcSEcCtD
Lenalidomide—Abdominal pain—Ezetimibe—atherosclerosis	0.000207	0.00102	CcSEcCtD
Lenalidomide—Body temperature increased—Ezetimibe—atherosclerosis	0.000207	0.00102	CcSEcCtD
Lenalidomide—Paraesthesia—Niacin—atherosclerosis	0.000206	0.00101	CcSEcCtD
Lenalidomide—Feeling abnormal—Simvastatin—atherosclerosis	0.000206	0.00101	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000206	0.00101	CcSEcCtD
Lenalidomide—Dyspnoea—Niacin—atherosclerosis	0.000205	0.001	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000205	0.001	CcSEcCtD
Lenalidomide—Insomnia—Pravastatin—atherosclerosis	0.000205	0.001	CcSEcCtD
Lenalidomide—Somnolence—Niacin—atherosclerosis	0.000204	0.001	CcSEcCtD
Lenalidomide—Paraesthesia—Pravastatin—atherosclerosis	0.000203	0.000996	CcSEcCtD
Lenalidomide—Dyspepsia—Niacin—atherosclerosis	0.000202	0.000992	CcSEcCtD
Lenalidomide—Dyspnoea—Pravastatin—atherosclerosis	0.000202	0.000989	CcSEcCtD
Lenalidomide—Decreased appetite—Niacin—atherosclerosis	0.0002	0.000979	CcSEcCtD
Lenalidomide—Dyspepsia—Pravastatin—atherosclerosis	0.000199	0.000977	CcSEcCtD
Lenalidomide—Rash—Rosuvastatin—atherosclerosis	0.000199	0.000976	CcSEcCtD
Lenalidomide—Dermatitis—Rosuvastatin—atherosclerosis	0.000199	0.000975	CcSEcCtD
Lenalidomide—Urticaria—Simvastatin—atherosclerosis	0.000199	0.000975	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Niacin—atherosclerosis	0.000198	0.000973	CcSEcCtD
Lenalidomide—Abdominal pain—Simvastatin—atherosclerosis	0.000198	0.00097	CcSEcCtD
Lenalidomide—Body temperature increased—Simvastatin—atherosclerosis	0.000198	0.00097	CcSEcCtD
Lenalidomide—Headache—Rosuvastatin—atherosclerosis	0.000198	0.00097	CcSEcCtD
Lenalidomide—Hypersensitivity—Lovastatin—atherosclerosis	0.000197	0.000967	CcSEcCtD
Lenalidomide—Decreased appetite—Pravastatin—atherosclerosis	0.000197	0.000964	CcSEcCtD
Lenalidomide—Pain—Niacin—atherosclerosis	0.000197	0.000963	CcSEcCtD
Lenalidomide—Fatigue—Pravastatin—atherosclerosis	0.000195	0.000956	CcSEcCtD
Lenalidomide—Pain—Pravastatin—atherosclerosis	0.000194	0.000949	CcSEcCtD
Lenalidomide—Constipation—Pravastatin—atherosclerosis	0.000194	0.000949	CcSEcCtD
Lenalidomide—Hypersensitivity—Ezetimibe—atherosclerosis	0.000193	0.000948	CcSEcCtD
Lenalidomide—Asthenia—Lovastatin—atherosclerosis	0.000192	0.000941	CcSEcCtD
Lenalidomide—Pruritus—Lovastatin—atherosclerosis	0.000189	0.000928	CcSEcCtD
Lenalidomide—Asthenia—Ezetimibe—atherosclerosis	0.000188	0.000923	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Niacin—atherosclerosis	0.000188	0.000921	CcSEcCtD
Lenalidomide—Nausea—Rosuvastatin—atherosclerosis	0.000188	0.000919	CcSEcCtD
Lenalidomide—Feeling abnormal—Pravastatin—atherosclerosis	0.000186	0.000914	CcSEcCtD
Lenalidomide—Pruritus—Ezetimibe—atherosclerosis	0.000186	0.00091	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000185	0.000907	CcSEcCtD
Lenalidomide—Hypersensitivity—Simvastatin—atherosclerosis	0.000184	0.000904	CcSEcCtD
Lenalidomide—Diarrhoea—Lovastatin—atherosclerosis	0.000183	0.000898	CcSEcCtD
Lenalidomide—Urticaria—Niacin—atherosclerosis	0.000183	0.000895	CcSEcCtD
Lenalidomide—Abdominal pain—Niacin—atherosclerosis	0.000182	0.000891	CcSEcCtD
Lenalidomide—Body temperature increased—Niacin—atherosclerosis	0.000182	0.000891	CcSEcCtD
Lenalidomide—Urticaria—Pravastatin—atherosclerosis	0.00018	0.000881	CcSEcCtD
Lenalidomide—Asthenia—Simvastatin—atherosclerosis	0.00018	0.00088	CcSEcCtD
Lenalidomide—Diarrhoea—Ezetimibe—atherosclerosis	0.00018	0.00088	CcSEcCtD
Lenalidomide—Body temperature increased—Pravastatin—atherosclerosis	0.000179	0.000877	CcSEcCtD
Lenalidomide—Abdominal pain—Pravastatin—atherosclerosis	0.000179	0.000877	CcSEcCtD
Lenalidomide—Pruritus—Simvastatin—atherosclerosis	0.000177	0.000868	CcSEcCtD
Lenalidomide—Dizziness—Lovastatin—atherosclerosis	0.000177	0.000867	CcSEcCtD
Lenalidomide—Dizziness—Ezetimibe—atherosclerosis	0.000174	0.000851	CcSEcCtD
Lenalidomide—Diarrhoea—Simvastatin—atherosclerosis	0.000171	0.00084	CcSEcCtD
Lenalidomide—Vomiting—Lovastatin—atherosclerosis	0.00017	0.000834	CcSEcCtD
Lenalidomide—Hypersensitivity—Niacin—atherosclerosis	0.000169	0.00083	CcSEcCtD
Lenalidomide—Rash—Lovastatin—atherosclerosis	0.000169	0.000827	CcSEcCtD
Lenalidomide—Dermatitis—Lovastatin—atherosclerosis	0.000169	0.000826	CcSEcCtD
Lenalidomide—Headache—Lovastatin—atherosclerosis	0.000168	0.000822	CcSEcCtD
Lenalidomide—Vomiting—Ezetimibe—atherosclerosis	0.000167	0.000818	CcSEcCtD
Lenalidomide—Hypersensitivity—Pravastatin—atherosclerosis	0.000167	0.000817	CcSEcCtD
Lenalidomide—Dizziness—Simvastatin—atherosclerosis	0.000166	0.000811	CcSEcCtD
Lenalidomide—Rash—Ezetimibe—atherosclerosis	0.000165	0.000811	CcSEcCtD
Lenalidomide—Dermatitis—Ezetimibe—atherosclerosis	0.000165	0.000811	CcSEcCtD
Lenalidomide—Asthenia—Niacin—atherosclerosis	0.000165	0.000808	CcSEcCtD
Lenalidomide—Headache—Ezetimibe—atherosclerosis	0.000164	0.000806	CcSEcCtD
Lenalidomide—Pruritus—Niacin—atherosclerosis	0.000163	0.000797	CcSEcCtD
Lenalidomide—Asthenia—Pravastatin—atherosclerosis	0.000162	0.000796	CcSEcCtD
Lenalidomide—Pruritus—Pravastatin—atherosclerosis	0.00016	0.000785	CcSEcCtD
Lenalidomide—Vomiting—Simvastatin—atherosclerosis	0.000159	0.00078	CcSEcCtD
Lenalidomide—Nausea—Lovastatin—atherosclerosis	0.000159	0.000779	CcSEcCtD
Lenalidomide—Rash—Simvastatin—atherosclerosis	0.000158	0.000774	CcSEcCtD
Lenalidomide—Dermatitis—Simvastatin—atherosclerosis	0.000158	0.000773	CcSEcCtD
Lenalidomide—Diarrhoea—Niacin—atherosclerosis	0.000157	0.000771	CcSEcCtD
Lenalidomide—Headache—Simvastatin—atherosclerosis	0.000157	0.000769	CcSEcCtD
Lenalidomide—Nausea—Ezetimibe—atherosclerosis	0.000156	0.000764	CcSEcCtD
Lenalidomide—Diarrhoea—Pravastatin—atherosclerosis	0.000155	0.000759	CcSEcCtD
Lenalidomide—Dizziness—Niacin—atherosclerosis	0.000152	0.000745	CcSEcCtD
Lenalidomide—Dizziness—Pravastatin—atherosclerosis	0.00015	0.000734	CcSEcCtD
Lenalidomide—Nausea—Simvastatin—atherosclerosis	0.000149	0.000729	CcSEcCtD
Lenalidomide—Vomiting—Niacin—atherosclerosis	0.000146	0.000716	CcSEcCtD
Lenalidomide—Rash—Niacin—atherosclerosis	0.000145	0.00071	CcSEcCtD
Lenalidomide—Dermatitis—Niacin—atherosclerosis	0.000145	0.00071	CcSEcCtD
Lenalidomide—Headache—Niacin—atherosclerosis	0.000144	0.000706	CcSEcCtD
Lenalidomide—Vomiting—Pravastatin—atherosclerosis	0.000144	0.000705	CcSEcCtD
Lenalidomide—Rash—Pravastatin—atherosclerosis	0.000143	0.000699	CcSEcCtD
Lenalidomide—Dermatitis—Pravastatin—atherosclerosis	0.000143	0.000699	CcSEcCtD
Lenalidomide—Headache—Pravastatin—atherosclerosis	0.000142	0.000695	CcSEcCtD
Lenalidomide—Nausea—Niacin—atherosclerosis	0.000137	0.000669	CcSEcCtD
Lenalidomide—Nausea—Pravastatin—atherosclerosis	0.000134	0.000659	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—APOB—atherosclerosis	8.63e-05	0.000645	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TLR4—atherosclerosis	8.63e-05	0.000645	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EDN1—atherosclerosis	8.49e-05	0.000635	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL5—atherosclerosis	8.43e-05	0.00063	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—ICAM1—atherosclerosis	8.28e-05	0.000619	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LPL—atherosclerosis	8.24e-05	0.000616	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—NOS2—atherosclerosis	8.21e-05	0.000614	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ABCG1—atherosclerosis	8.13e-05	0.000607	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—atherosclerosis	8.1e-05	0.000606	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PRKCG—atherosclerosis	8.01e-05	0.000599	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IFNG—atherosclerosis	7.96e-05	0.000595	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SPP1—atherosclerosis	7.81e-05	0.000584	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—atherosclerosis	7.8e-05	0.000583	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—FABP4—atherosclerosis	7.64e-05	0.000571	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—LCAT—atherosclerosis	7.64e-05	0.000571	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SIRT1—atherosclerosis	7.6e-05	0.000568	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOA4—atherosclerosis	7.5e-05	0.000561	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCL2—atherosclerosis	7.41e-05	0.000554	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP7A1—atherosclerosis	7.37e-05	0.000551	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ABCG4—atherosclerosis	7.23e-05	0.00054	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PDGFB—atherosclerosis	7.22e-05	0.00054	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL1B—atherosclerosis	7.1e-05	0.000531	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AGT—atherosclerosis	7.05e-05	0.000527	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ABCG8—atherosclerosis	6.93e-05	0.000518	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LEP—atherosclerosis	6.91e-05	0.000516	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APOE—atherosclerosis	6.91e-05	0.000516	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CAV1—atherosclerosis	6.84e-05	0.000512	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APOA1—atherosclerosis	6.83e-05	0.00051	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP27A1—atherosclerosis	6.81e-05	0.000509	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—atherosclerosis	6.77e-05	0.000506	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—atherosclerosis	6.69e-05	0.0005	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—NFKB1—atherosclerosis	6.63e-05	0.000495	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ESR1—atherosclerosis	6.6e-05	0.000493	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—F2—atherosclerosis	6.52e-05	0.000487	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALOX5AP—atherosclerosis	6.46e-05	0.000483	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALOX15—atherosclerosis	6.46e-05	0.000483	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLA2G2A—atherosclerosis	6.46e-05	0.000483	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOA2—atherosclerosis	6.46e-05	0.000483	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ABCG5—atherosclerosis	6.38e-05	0.000477	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IFNG—atherosclerosis	6.3e-05	0.000471	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CG—atherosclerosis	6.23e-05	0.000466	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—LPA—atherosclerosis	6.16e-05	0.00046	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IFNG—atherosclerosis	6.15e-05	0.00046	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOA5—atherosclerosis	5.9e-05	0.000441	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—INS—atherosclerosis	5.9e-05	0.000441	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL8—atherosclerosis	5.85e-05	0.000438	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL2—atherosclerosis	5.81e-05	0.000434	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—atherosclerosis	5.72e-05	0.000428	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CXCL8—atherosclerosis	5.72e-05	0.000428	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF1—atherosclerosis	5.71e-05	0.000427	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLA2G1B—atherosclerosis	5.68e-05	0.000425	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL1B—atherosclerosis	5.62e-05	0.00042	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LDLRAP1—atherosclerosis	5.62e-05	0.00042	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALOX5—atherosclerosis	5.49e-05	0.00041	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL1B—atherosclerosis	5.49e-05	0.00041	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ABCG1—atherosclerosis	5.48e-05	0.000409	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SERPINE1—atherosclerosis	5.42e-05	0.000405	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—atherosclerosis	5.39e-05	0.000403	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—atherosclerosis	5.37e-05	0.000401	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—atherosclerosis	5.3e-05	0.000396	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLTP—atherosclerosis	5.28e-05	0.000395	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOS3—atherosclerosis	5.18e-05	0.000387	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—atherosclerosis	5.15e-05	0.000385	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CYP7A1—atherosclerosis	4.97e-05	0.000371	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—atherosclerosis	4.95e-05	0.00037	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	4.89e-05	0.000366	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	4.86e-05	0.000363	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	4.83e-05	0.000361	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—atherosclerosis	4.8e-05	0.000359	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	4.72e-05	0.000353	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—atherosclerosis	4.65e-05	0.000347	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—atherosclerosis	4.59e-05	0.000343	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCG8—atherosclerosis	4.58e-05	0.000342	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LTA4H—atherosclerosis	4.58e-05	0.000342	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	4.52e-05	0.000338	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MAPK3—atherosclerosis	4.5e-05	0.000336	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TRPV1—atherosclerosis	4.47e-05	0.000334	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TGFB1—atherosclerosis	4.36e-05	0.000326	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ABCG5—atherosclerosis	4.3e-05	0.000321	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	4.27e-05	0.000319	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TGFB1—atherosclerosis	4.27e-05	0.000319	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—atherosclerosis	4.16e-05	0.000311	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MMP9—atherosclerosis	4.15e-05	0.00031	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NFKB1—atherosclerosis	4.11e-05	0.000307	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—atherosclerosis	4.08e-05	0.000305	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—atherosclerosis	4.06e-05	0.000303	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MAPK8—atherosclerosis	4.04e-05	0.000302	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOA4—atherosclerosis	3.99e-05	0.000298	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TNF—atherosclerosis	3.98e-05	0.000298	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LDLRAP1—atherosclerosis	3.98e-05	0.000298	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	3.81e-05	0.000284	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLTP—atherosclerosis	3.74e-05	0.00028	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—atherosclerosis	3.73e-05	0.000279	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STAT3—atherosclerosis	3.69e-05	0.000276	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCG1—atherosclerosis	3.62e-05	0.000271	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—atherosclerosis	3.56e-05	0.000266	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MAPK3—atherosclerosis	3.53e-05	0.000264	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—atherosclerosis	3.51e-05	0.000262	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK8—atherosclerosis	3.5e-05	0.000262	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOA2—atherosclerosis	3.43e-05	0.000257	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—atherosclerosis	3.42e-05	0.000256	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFB1—atherosclerosis	3.42e-05	0.000256	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—FABP4—atherosclerosis	3.4e-05	0.000254	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LCAT—atherosclerosis	3.4e-05	0.000254	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOA4—atherosclerosis	3.34e-05	0.00025	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—atherosclerosis	3.29e-05	0.000246	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP7A1—atherosclerosis	3.28e-05	0.000245	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LTA4H—atherosclerosis	3.25e-05	0.000243	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ABCG8—atherosclerosis	3.25e-05	0.000243	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	3.23e-05	0.000242	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CETP—atherosclerosis	3.18e-05	0.000238	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BGN—atherosclerosis	3.17e-05	0.000237	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	3.13e-05	0.000234	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	3.06e-05	0.000229	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP27A1—atherosclerosis	3.03e-05	0.000227	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	2.99e-05	0.000223	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	2.97e-05	0.000222	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	2.91e-05	0.000218	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—atherosclerosis	2.91e-05	0.000218	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALOX15—atherosclerosis	2.88e-05	0.000215	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALOX5AP—atherosclerosis	2.88e-05	0.000215	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLA2G2A—atherosclerosis	2.88e-05	0.000215	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOA2—atherosclerosis	2.88e-05	0.000215	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCG5—atherosclerosis	2.84e-05	0.000212	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	2.84e-05	0.000212	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—PLAT—atherosclerosis	2.8e-05	0.00021	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	2.77e-05	0.000207	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CST3—atherosclerosis	2.76e-05	0.000207	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LPA—atherosclerosis	2.74e-05	0.000205	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—BGN—atherosclerosis	2.66e-05	0.000199	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	2.64e-05	0.000197	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOA5—atherosclerosis	2.63e-05	0.000197	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NAMPT—atherosclerosis	2.62e-05	0.000196	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOC3—atherosclerosis	2.59e-05	0.000193	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—atherosclerosis	2.58e-05	0.000193	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—LDLR—atherosclerosis	2.57e-05	0.000192	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ABCG1—atherosclerosis	2.57e-05	0.000192	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	2.55e-05	0.000191	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLA2G1B—atherosclerosis	2.53e-05	0.000189	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—atherosclerosis	2.53e-05	0.000189	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	2.5e-05	0.000187	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atherosclerosis	2.48e-05	0.000186	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HSPA1B—atherosclerosis	2.48e-05	0.000186	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	2.48e-05	0.000185	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	2.47e-05	0.000185	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALOX5—atherosclerosis	2.44e-05	0.000183	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—FABP4—atherosclerosis	2.41e-05	0.00018	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LCAT—atherosclerosis	2.41e-05	0.00018	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NCF1—atherosclerosis	2.4e-05	0.00018	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—PLG—atherosclerosis	2.38e-05	0.000178	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—atherosclerosis	2.38e-05	0.000178	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOA4—atherosclerosis	2.37e-05	0.000177	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP7A1—atherosclerosis	2.33e-05	0.000174	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	2.29e-05	0.000171	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CYBA—atherosclerosis	2.26e-05	0.000169	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	2.26e-05	0.000169	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PARP1—atherosclerosis	2.21e-05	0.000165	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	2.2e-05	0.000164	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NAMPT—atherosclerosis	2.19e-05	0.000164	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	2.18e-05	0.000163	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LIPC—atherosclerosis	2.18e-05	0.000163	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	2.17e-05	0.000162	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOC3—atherosclerosis	2.17e-05	0.000162	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LDLR—atherosclerosis	2.15e-05	0.000161	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP27A1—atherosclerosis	2.15e-05	0.000161	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—APOB—atherosclerosis	2.11e-05	0.000158	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	2.1e-05	0.000157	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CETP—atherosclerosis	2.1e-05	0.000157	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	2.06e-05	0.000154	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALOX15—atherosclerosis	2.04e-05	0.000152	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALOX5AP—atherosclerosis	2.04e-05	0.000152	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLA2G2A—atherosclerosis	2.04e-05	0.000152	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOA2—atherosclerosis	2.04e-05	0.000152	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SCARB1—atherosclerosis	2.01e-05	0.00015	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ABCG5—atherosclerosis	2.01e-05	0.00015	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	1.97e-05	0.000147	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.96e-05	0.000147	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LPA—atherosclerosis	1.94e-05	0.000145	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HMGCR—atherosclerosis	1.9e-05	0.000142	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BGN—atherosclerosis	1.88e-05	0.000141	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOA5—atherosclerosis	1.86e-05	0.000139	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLA2G1B—atherosclerosis	1.79e-05	0.000134	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.78e-05	0.000133	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALOX5—atherosclerosis	1.73e-05	0.00013	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCA1—atherosclerosis	1.69e-05	0.000127	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.67e-05	0.000125	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOB—atherosclerosis	1.66e-05	0.000124	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—LPL—atherosclerosis	1.59e-05	0.000119	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NAMPT—atherosclerosis	1.55e-05	0.000116	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LIPC—atherosclerosis	1.54e-05	0.000115	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PRKCG—atherosclerosis	1.54e-05	0.000115	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOC3—atherosclerosis	1.54e-05	0.000115	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LDLR—atherosclerosis	1.53e-05	0.000114	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CETP—atherosclerosis	1.49e-05	0.000111	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	1.46e-05	0.000109	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HMOX1—atherosclerosis	1.45e-05	0.000109	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTHFR—atherosclerosis	1.43e-05	0.000107	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SCARB1—atherosclerosis	1.43e-05	0.000107	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOB—atherosclerosis	1.39e-05	0.000104	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PDGFB—atherosclerosis	1.39e-05	0.000104	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTM1—atherosclerosis	1.35e-05	0.000101	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HMGCR—atherosclerosis	1.35e-05	0.000101	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOE—atherosclerosis	1.33e-05	9.95e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LPL—atherosclerosis	1.33e-05	9.94e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	1.32e-05	9.88e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CAV1—atherosclerosis	1.32e-05	9.86e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOA1—atherosclerosis	1.32e-05	9.83e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GPX1—atherosclerosis	1.3e-05	9.7e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CD36—atherosclerosis	1.26e-05	9.44e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS2—atherosclerosis	1.24e-05	9.27e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ABCA1—atherosclerosis	1.2e-05	8.98e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTHFR—atherosclerosis	1.2e-05	8.95e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARA—atherosclerosis	1.17e-05	8.78e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AGT—atherosclerosis	1.14e-05	8.5e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—INS—atherosclerosis	1.14e-05	8.5e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOE—atherosclerosis	1.11e-05	8.33e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CAV1—atherosclerosis	1.1e-05	8.25e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOA1—atherosclerosis	1.1e-05	8.24e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SERPINE1—atherosclerosis	1.04e-05	7.81e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HMOX1—atherosclerosis	1.03e-05	7.7e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CG—atherosclerosis	1.01e-05	7.52e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS3—atherosclerosis	9.97e-06	7.45e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOB—atherosclerosis	9.87e-06	7.38e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—atherosclerosis	9.71e-06	7.26e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTM1—atherosclerosis	9.6e-06	7.18e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—INS—atherosclerosis	9.52e-06	7.12e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LPL—atherosclerosis	9.43e-06	7.05e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GPX1—atherosclerosis	9.2e-06	6.87e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CD36—atherosclerosis	8.96e-06	6.69e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—atherosclerosis	8.73e-06	6.53e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTHFR—atherosclerosis	8.49e-06	6.34e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NOS3—atherosclerosis	8.35e-06	6.24e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARA—atherosclerosis	8.33e-06	6.22e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AGT—atherosclerosis	8.06e-06	6.03e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOE—atherosclerosis	7.9e-06	5.91e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CAV1—atherosclerosis	7.83e-06	5.85e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOA1—atherosclerosis	7.81e-06	5.84e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CG—atherosclerosis	7.13e-06	5.33e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—atherosclerosis	7.11e-06	5.32e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—atherosclerosis	6.88e-06	5.14e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK3—atherosclerosis	6.8e-06	5.08e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—INS—atherosclerosis	6.75e-06	5.05e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—atherosclerosis	6.59e-06	4.93e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—atherosclerosis	6.19e-06	4.63e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NOS3—atherosclerosis	5.92e-06	4.42e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—atherosclerosis	5.41e-06	4.05e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—atherosclerosis	4.97e-06	3.71e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—atherosclerosis	4.58e-06	3.43e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—atherosclerosis	3.84e-06	2.87e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—atherosclerosis	2.72e-06	2.03e-05	CbGpPWpGaD
